Presented by Dr Pierre Frères (CHU de Liège, Belgium) & Prof Dr Maria De Santis (Charité Medical University Hospital, Berlin, Germany)
In this in-depth interview, Dr Pierre Frères speaks with Prof Dr Maria De Santis to discuss the POTOMAC trial, a global randomised phase III study evaluating durvalumab in combination with BCG induction and maintenance in BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).1
The study previously met its primary endpoint, showing a statistically significant and clinically meaningful improvement in disease-free survival with the addition of 1 year of durvalumab to BCG induction and maintenance therapy.
At ASCO 2026, the planned 5-year overall survival analysis and patient-reported outcomes were presented. With a median follow-up of 72 months, the addition of durvalumab showed no detriment in overall survival, with median overall survival not reached in either arm. The addition of durvalumab did not have a major impact on patient-reported quality of life, with generally similar patient-reported outcomes between treatment arms.
The interview also highlights ongoing clinical considerations, including the potential to reduce cystectomy rates, patient selection and the need to balance benefit against the risk of systemic immunotherapy. Overall, POTOMAC supports durvalumab plus BCG induction and maintenance as a new treatment option for selected patients with BCG-naïve, high-risk NMIBC, with shared decision-making remaining central.
Reference:
De Santis M, et al. ASCO 2026; Abstract 4624.
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in